There are currently 846 clinical trials in Jacksonville, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Florida, Mayo Clinic - Jacksonville, Mayo Clinic and Mayo Clinic Florida. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Robotic-Assisted da Vinci System Prophylactic Nipple-Sparing Mastectomy
NCT03892980
Recruiting
This study evaluates the safety and effectiveness of the da Vinci Surgical Systems in prophylactic Nipple Sparing Mastectomy procedures.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
06/16/2025
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Nipple Sparing Mastectomy
Register for Updates
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955
Recruiting
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Register for Updates
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Multiple Myeloma
Register for Updates
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
NCT06529419
Recruiting
A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/16/2025
Locations: Research Site, Jacksonville, Florida
Conditions: Asthma
Register for Updates
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
NCT05847569
Recruiting
This phase II trial tests alternate doses and dosing schedules of belantamab mafodotin in treating patients with triple-class multiple myeloma that has come back (after a period of improvement) (recurrent) and/or does not respond to treatment (or that has not responded to previous treatment) (refractory). Belantamab mafodotin is a monoclonal antibody, belantamab, linked to a chemotherapy drug, mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules (receptor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
NCT06770933
Recruiting
The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR). The primary objective of the study is to evaluate the efficacy of daily oral doses of VX-01 versus placebo following 52 weeks of treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Florida Retina Institute - Jacksonville Southside, Jacksonville, Florida
Conditions: Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Register for Updates
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
NCT06998056
Recruiting
This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).
Gender:
ALL
Ages:
Between 3 months and 2 years
Trial Updated:
06/13/2025
Locations: Arcutis Clinical Study Site 213, Jacksonville, Florida
Conditions: Atopic Dermatitis (Eczema)
Register for Updates
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
NCT05143177
Recruiting
This is an adaptive Phase 2/3 multicenter, double-blind, placebo-controlled, randomized, parallel, 2 arm study to evaluate the efficacy and safety of DA-1229 compared to placebo in patients with calcific aortic valve disease with mild to moderate aortic stenosis. There are 2 arms in this study to which patients will be randomized in a ratio of 1:1 to receive the DA-1229 or placebo orally once daily for a period of 104 weeks. The 2 arms are: placebo and DA-1229 10 mg Group. The study will have t... Read More
Gender:
ALL
Ages:
35 years and above
Trial Updated:
06/12/2025
Locations: Mayo Clinic, FL, Jacksonville, Florida
Conditions: Calcific Aortic Valve Disease
Register for Updates
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
NCT05268614
Recruiting
This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating free HPV DNA (cfHPV DNA) level, and cfHPV DNA clearance rate produces Local-Regional Control rates that are similar to what has been achieved with more aggressive therapy in patients with Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma (OPSCC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/12/2025
Locations: UF Health Proton Therapy Institute, Jacksonville, Florida
Conditions: Oropharyngeal Squamous Cell Carcinoma
Register for Updates
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289
Recruiting
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/12/2025
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Lupus Nephritis
Register for Updates
Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
NCT06999122
Recruiting
The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic stroke). Stroke is a medical emergency and must be quickly diagnosed and treated. Computed tomography (CT) or magnetic resonance imaging (MRI) scans are commonly used to diagnose stroke,... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
06/12/2025
Locations: Mayo Jacksonville, Jacksonville, Florida
Conditions: Stroke, Hemorrhagic Stroke
Register for Updates
RECOVER-SLEEP: Platform Protocol
NCT06404086
Recruiting
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospect... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: University of Florida College of Medicine Jacksonville, Jacksonville, Florida
Conditions: Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
Register for Updates